{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T06:22:22Z","timestamp":1767853342711,"version":"3.49.0"},"reference-count":55,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T00:00:00Z","timestamp":1723248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>To help navigate the complex treatment landscape of ulcerative colitis (UC), we quantified the benefit-risk trade-offs that patients were willing to make when choosing treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients completed an online discrete choice experiment. Eligible patients had a UC diagnosis for \u22656 months, were aged \u226518 years, and resided in France, Germany, Italy, Spain, or the UK. Patients chose between 2 hypothetical treatments set up to ensure trade-offs were made. Clinical trial data, literature review, and patient interviews identified treatment attributes. Relative attribute importance (RAI) scores and maximum acceptable risks were generated. A patient-centric benefit-risk assessment of 200 mg of filgotinib was conducted as an example to show how measured trade-offs can be used.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Overall, 631 patients participated; patients had a mean age of 42.2 years and were predominantly male (75.3%). Achieving and maintaining clinical remission was the most important factor for patients (RAI 32.4%); to achieve this, patients were willing to accept slightly higher risks of blood clots, serious infections, and malignancies compared with lower risk treatment profiles. Patients also valued the convenience of oral treatments, avoiding steroids, and the ability to attend school\/work. The patient-centric benefit-risk assessment suggested patients are significantly more likely to prefer Janus kinase 1 preferential inhibitor filgotinib over placebo.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Achieving clinical remission was the highest treatment priority for patients. To attain this, patients were willing to accept some slightly higher risk treatment profiles. Patient choices in the benefit-risk assessment suggested patients were significantly more likely to prefer filgotinib over placebo.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ibd\/izae162","type":"journal-article","created":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T12:26:21Z","timestamp":1720095981000},"page":"1281-1294","source":"Crossref","is-referenced-by-count":5,"title":["Benefit-Risk Trade-offs and Patient Preferences for Therapy Selection in Ulcerative Colitis: a Multicountry Preference Study"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2090-3445","authenticated-orcid":false,"given":"Javier P","family":"Gisbert","sequence":"first","affiliation":[{"name":"Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigaci\u00f3n Sanitaria Princesa (IIS-Princesa), Universidad Aut\u00f3noma de Madrid (UAM) , Madrid ,","place":["Spain"]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBERehd), Carlos III Health Institute , Madrid ,","place":["Spain"]}]},{"given":"Stefan","family":"Schreiber","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Kiel University, University Hospital Schleswig-Holstein , Kiel ,","place":["Germany"]}]},{"given":"Corey A","family":"Siegel","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Center, Section of Gastroenterology & Hepatology, Dartmouth-Hitchcock Medical Center , Lebanon, NH ,","place":["USA"]},{"name":"The Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth , Hanover, NH ,","place":["USA"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2634-9668","authenticated-orcid":false,"given":"Fernando","family":"Magro","sequence":"additional","affiliation":[{"name":"CINTESIS@RISE, Faculty of Medicine, University of Porto , Porto ,","place":["Portugal"]}]},{"given":"Anna","family":"Jus","sequence":"additional","affiliation":[{"name":"Galapagos NV , Leiden ,","place":["Netherlands"]}]},{"given":"Chiara","family":"Whichello","sequence":"additional","affiliation":[{"name":"Evidera Inc. , London ,","place":["UK"]}]},{"given":"Christine","family":"Michaels-Igbokwe","sequence":"additional","affiliation":[{"name":"Evidera Inc. , Montreal, QC ,","place":["Canada"]}]},{"given":"Sebastian","family":"Heidenreich","sequence":"additional","affiliation":[{"name":"Evidera Inc. , London ,","place":["UK"]}]},{"given":"Alessandra","family":"Oortwijn","sequence":"additional","affiliation":[{"name":"Galapagos NV , Leiden ,","place":["Netherlands"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9942-3019","authenticated-orcid":false,"given":"S\u00e9verine","family":"Vermeire","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, UZ Leuven , Leuven ,","place":["Belgium"]}]}],"member":"286","published-online":{"date-parts":[[2024,8,10]]},"reference":[{"key":"2025051303571747900_CIT0001","doi-asserted-by":"publisher","first-page":"212572","DOI":"10.7573\/dic.212572","article-title":"New developments in ulcerative colitis: latest evidence on management, treatment, and maintenance","volume":"8","author":"Tripathi","year":"2019","journal-title":"Drugs Context"},{"issue":"10080","key":"2025051303571747900_CIT0002","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet."},{"issue":"4","key":"2025051303571747900_CIT0003","first-page":"235","article-title":"Extraintestinal manifestations of inflammatory bowel disease","volume":"7","author":"Levine","year":"2011","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"5","key":"2025051303571747900_CIT0004","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1097\/01.MIB.0000218762.61217.4a","article-title":"Relationship between sick leave, unemployment, disability, and health-related quality of life in patients with inflammatory bowel disease","volume":"12","author":"Bernklev","year":"2006","journal-title":"Inflamm Bowel Dis."},{"issue":"7","key":"2025051303571747900_CIT0005","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.dld.2021.03.002","article-title":"Quality of life in patients with moderate to severe ulcerative colitis and the impact of treatment: a narrative review","volume":"53","author":"Armuzzi","year":"2021","journal-title":"Dig Liver Dis."},{"issue":"12","key":"2025051303571747900_CIT0006","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1002\/ibd.20520","article-title":"Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis","volume":"14","author":"Lewis","year":"2008","journal-title":"Inflamm Bowel Dis."},{"issue":"8","key":"2025051303571747900_CIT0007","doi-asserted-by":"publisher","first-page":"e28502","DOI":"10.7759\/cureus.28502","article-title":"Quality of life in patients with inflammatory bowel disease: importance of psychological symptoms","volume":"14","author":"Mitropoulou","year":"2022","journal-title":"Cureus"},{"issue":"2","key":"2025051303571747900_CIT0008","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1007\/s12325-022-02364-2","article-title":"Burden of fatigue among patients with ulcerative colitis and Crohn\u2019s disease: results from a global survey of patients and gastroenterologists","volume":"40","author":"Regueiro","year":"2023","journal-title":"Adv Ther."},{"issue":"1","key":"2025051303571747900_CIT0009","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J Crohns Colitis."},{"issue":"1","key":"2025051303571747900_CIT0010","doi-asserted-by":"publisher","first-page":"u211063.w4361","DOI":"10.1136\/bmjquality.u211063.w4361","article-title":"Improving clinical remission rates in pediatric inflammatory bowel disease with previsit planning","volume":"5","author":"Savarino","year":"2016","journal-title":"BMJ Qual Improv Rep"},{"key":"2025051303571747900_CIT0011","doi-asserted-by":"publisher","first-page":"17562848221138160","DOI":"10.1177\/17562848221138160","article-title":"A review of the therapeutic management of ulcerative colitis","volume":"15","author":"Aslam","year":"2022","journal-title":"Therap Adv Gastroenterol"},{"issue":"4","key":"2025051303571747900_CIT0012","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/S2468-1253(23)00008-0","article-title":"Combination biologic therapy for ulcerative colitis","volume":"8","author":"Vermeire","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"2025051303571747900_CIT0013","first-page":"360","article-title":"Advances in IBD: current developments in the treatment of inflammatory bowel diseases","volume":"6","author":"Moss","year":"2022","journal-title":"Gastroenterol Hepatol."},{"issue":"9","key":"2025051303571747900_CIT0014","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1093\/ecco-jcc\/jjz042","article-title":"Real-world effectiveness and safety of vedolizumab for the treatment of inflammatory bowel disease: the Scottish vedolizumab cohort","volume":"13","author":"Plevris","year":"2019","journal-title":"J Crohns Colitis."},{"issue":"2","key":"2025051303571747900_CIT0015","doi-asserted-by":"publisher","first-page":"e0149692","DOI":"10.1371\/journal.pone.0149692","article-title":"Dose escalation and healthcare resource use among ulcerative colitis patients treated with adalimumab in English hospitals: an analysis of real-world data","volume":"11","author":"Black","year":"2016","journal-title":"PLoS One."},{"issue":"10","key":"2025051303571747900_CIT0016","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.3390\/jcm10102132","article-title":"Frequency and effectiveness of empirical anti-TNF dose intensification in inflammatory bowel disease: systematic review with meta-analysis","volume":"10","author":"Guberna","year":"2021","journal-title":"J Clin Med"},{"issue":"6","key":"2025051303571747900_CIT0017","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1093\/ibd\/izz204","article-title":"Real-world effectiveness of advanced therapies among patients with moderate to severe ulcerative colitis in the United States","volume":"26","author":"Long","year":"2020","journal-title":"Inflamm Bowel Dis."},{"key":"2025051303571747900_CIT0018","author":"National Institute for Health and Care Excellence"},{"issue":"37","key":"2025051303571747900_CIT0019","doi-asserted-by":"publisher","first-page":"13234","DOI":"10.3748\/wjg.v20.i37.13234","article-title":"Biological therapy for ulcerative colitis: an update","volume":"20","author":"Seo","year":"2014","journal-title":"World J Gastroenterol."},{"issue":"1","key":"2025051303571747900_CIT0020","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s11938-017-0120-8","article-title":"Update on the use of biologic therapy in ulcerative colitis","volume":"15","author":"Aggarwal","year":"2017","journal-title":"Curr Treat Options Gastroenterol"},{"issue":"10383","key":"2025051303571747900_CIT0021","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","article-title":"Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies","volume":"401","author":"Sandborn","year":"2023","journal-title":"Lancet."},{"key":"2025051303571747900_CIT0022","doi-asserted-by":"publisher","first-page":"1089099","DOI":"10.3389\/fmed.2023.1089099","article-title":"JAK inhibitors: a new dawn for oral therapies in inflammatory bowel diseases","volume":"10","author":"Herrera-deGuise","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"2025051303571747900_CIT0023","article-title":"European Medicines Agency","author":"RINVOQ product information"},{"key":"2025051303571747900_CIT0024","article-title":"European Medicines Agency","author":"XELJANZ product information"},{"key":"2025051303571747900_CIT0025","article-title":"European Medicines Agency","author":"Jyseleca product information"},{"issue":"7","key":"2025051303571747900_CIT0026","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1093\/ecco-jcc\/jjx009","article-title":"Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management","volume":"11","author":"Harbord","year":"2017","journal-title":"J Crohns Colitis."},{"issue":"9","key":"2025051303571747900_CIT0027","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/ajg.2015.233","article-title":"Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target","volume":"110","author":"Peyrin-Biroulet","year":"2015","journal-title":"Am J Gastroenterol."},{"issue":"6","key":"2025051303571747900_CIT0028","doi-asserted-by":"publisher","first-page":"874","DOI":"10.14309\/ajg.0000000000000183","article-title":"A treat-to-target update in ulcerative colitis: a systematic review","volume":"114","author":"Ungaro","year":"2019","journal-title":"Am J Gastroenterol."},{"issue":"Supplement_1","key":"2025051303571747900_CIT0029","doi-asserted-by":"publisher","first-page":"i311","DOI":"10.1093\/ecco-jcc\/jjac190.0281","article-title":"Assessing comprehensive remission for ulcerative colitis in clinical practice: international consensus recommendations","volume":"17","author":"Schreiber","year":"2023","journal-title":"J Crohns Colitis."},{"issue":"4","key":"2025051303571747900_CIT0030","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s40271-013-0031-2","article-title":"Assessing patient preferences for treatment options and process of care in inflammatory bowel disease: a critical review of quantitative data","volume":"6","author":"Bewtra","year":"2013","journal-title":"Patient"},{"issue":"10","key":"2025051303571747900_CIT0031","doi-asserted-by":"publisher","first-page":"e32365","DOI":"10.2196\/32365","article-title":"Understanding uptake of digital health products: methodology tutorial for a discrete choice experiment using the Bayesian efficient design","volume":"23","author":"Szinay","year":"2021","journal-title":"J Med Internet Res."},{"issue":"1","key":"2025051303571747900_CIT0032","doi-asserted-by":"publisher","first-page":"e0227635","DOI":"10.1371\/journal.pone.0227635","article-title":"Patient preferences for maintenance therapy in Crohn\u2019s disease: a discrete-choice experiment","volume":"15","author":"Hazlewood","year":"2020","journal-title":"PLoS One."},{"key":"2025051303571747900_CIT0033","doi-asserted-by":"publisher","first-page":"263","DOI":"10.2147\/CEG.S206970","article-title":"Patient and physician preferences for ulcerative colitis treatments in the United States","volume":"12","author":"Boeri","year":"2019","journal-title":"Clin Exp Gastroenterol"},{"issue":"1","key":"2025051303571747900_CIT0034","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/01.MIB.0000437498.14804.50","article-title":"Patient preferences for surgical versus medical therapy for ulcerative colitis","volume":"20","author":"Bewtra","year":"2014","journal-title":"Inflamm Bowel Dis."},{"key":"2025051303571747900_CIT0035","article-title":"The cutting edge in experimental design","author":"Choice Metrics Ngene 1.2 User Manual and Reference Guide"},{"issue":"7","key":"2025051303571747900_CIT0036","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/j.drudis.2019.05.001","article-title":"Methods for exploring and eliciting patient preferences in the medical product lifecycle: a literature review","volume":"24","author":"Soekhai","year":"2019","journal-title":"Drug Discov Today."},{"issue":"3","key":"2025051303571747900_CIT0037","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/hec.1369","article-title":"Rationalising the \u2018irrational\u2019: a think aloud study of discrete choice experiment responses","volume":"18","author":"Ryan","year":"2009","journal-title":"Health Econ."},{"issue":"10292","key":"2025051303571747900_CIT0038","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1016\/S0140-6736(21)00666-8","article-title":"Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b\/3 double-blind, randomised, placebo-controlled trial","volume":"397","author":"Feagan","year":"2021","journal-title":"Lancet."},{"issue":"7","key":"2025051303571747900_CIT0039","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1080\/00365521.2022.2036808","article-title":"Patient preferences for treatment in steroid resistant ulcerative colitis - a discrete-choice experiment","volume":"57","author":"Wickramasekera","year":"2022","journal-title":"Scand J Gastroenterol."},{"issue":"2","key":"2025051303571747900_CIT0040","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1007\/s12160-016-9845-1","article-title":"Lay awareness of the relationship between age and cancer risk","volume":"51","author":"Taber","year":"2017","journal-title":"Ann Behav Med."},{"issue":"Suppl 1","key":"2025051303571747900_CIT0041","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000509544","article-title":"Malignancies in inflammatory bowel disease","volume":"101","author":"Greuter","year":"2020","journal-title":"Digestion."},{"key":"2025051303571747900_CIT0042","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2147\/CEG.S243478","article-title":"Cardiovascular risk in individuals with inflammatory bowel disease","volume":"13","author":"Biondi","year":"2020","journal-title":"Clin Exp Gastroenterol"},{"issue":"4","key":"2025051303571747900_CIT0043","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/s41424-018-0013-8","article-title":"Risk of thrombosis and mortality in inflammatory bowel disease","volume":"9","author":"Andrade","year":"2018","journal-title":"Clin Transl Gastroenterol"},{"key":"2025051303571747900_CIT0044","article-title":"Highlights of Prescribing Information: OLUMIANT (baricitinib) tablets, for oral use","author":"Food and Drug Administration, Eli Lilly"},{"issue":"5","key":"2025051303571747900_CIT0045","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s40259-018-0304-3","article-title":"Risk of adverse drug events observed with baricitinib 2 mg versus baricitinib 4 mg once daily for the treatment of rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials","volume":"32","author":"Huang","year":"2018","journal-title":"BioDrugs"},{"key":"2025051303571747900_CIT0046","article-title":"Janus kinase (JAK) inhibitors: new measures to reduce risks of major cardiovascular events, malignancy, venous thromboembolism, serious infections and increased mortality"},{"issue":"9","key":"2025051303571747900_CIT0047","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1111\/apt.17674","article-title":"Integrated safety analysis of filgotinib for ulcerative colitis: results from SELECTION and SELECTIONLTE","volume":"58","author":"Schreiber","year":"2023","journal-title":"Aliment Pharmacol Ther."},{"issue":"9","key":"2025051303571747900_CIT0048","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1007\/s10620-020-06647-y","article-title":"Impaired quality of working life in inflammatory bowel disease patients","volume":"66","author":"Van Gennep","year":"2021","journal-title":"Dig Dis Sci."},{"issue":"12","key":"2025051303571747900_CIT0049","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1016\/j.cgh.2014.03.032","article-title":"Effects of inflammatory bowel disease on students\u2019 adjustment to college","volume":"12","author":"Almadani","year":"2014","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"Suppl 1","key":"2025051303571747900_CIT0050","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1159\/000504701","article-title":"Swiss IBDnet.Gender differences in inflammatory bowel disease","volume":"101","author":"Greuter","year":"2020","journal-title":"Digestion."},{"key":"2025051303571747900_CIT0051","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2147\/CEG.S359367","article-title":"Sexual dysfunction in female patients with inflammatory bowel disease: an overview","volume":"15","author":"Boyd","year":"2022","journal-title":"Clin Exp Gastroenterol."},{"issue":"5","key":"2025051303571747900_CIT0052","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology."},{"issue":"6","key":"2025051303571747900_CIT0053","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1093\/ecco-jcc\/jjad018","article-title":"Filgotinib improved health-related quality of life and led to comprehensive disease control in individuals with ulcerative colitis: data from the SELECTION trial","volume":"17","author":"Schreiber","year":"2023","journal-title":"J Crohns Colitis."},{"issue":"2","key":"2025051303571747900_CIT0054","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.jval.2018.07.876","article-title":"The internal validity of discrete choice experiment data: a testing tool for quantitative assessments","volume":"22","author":"Johnson","year":"2019","journal-title":"Value Health."},{"issue":"2","key":"2025051303571747900_CIT0055","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1093\/ecco-jcc\/jjac130","article-title":"Patients with inflammatory bowel disease have heterogeneous treatment preferences that are largely determined by the avoidance of abdominal pain and side effects [P-POWER IBD study]","volume":"17","author":"Louis","year":"2023","journal-title":"J Crohns Colitis."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izae162\/58795245\/izae162.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/31\/5\/1281\/58795245\/izae162.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/31\/5\/1281\/58795245\/izae162.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T07:57:26Z","timestamp":1747123046000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/31\/5\/1281\/7731363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,10]]},"references-count":55,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,8,10]]},"published-print":{"date-parts":[[2025,5,12]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izae162","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2024,8,10]]}}}